santacruzamate A

HDAC2 inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; structure in first source

Also Known As:

CAY10683; ethyl 3-(phenethylcarbamoyl)propylcarbamate; ethyl N-(4-oxo-4-(2-phenylethylamino)butyl)carbamate

Networked: 7 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Carbamates: 945
      - santacruzamate A: 7

Experts

1.	Wang, Yao: 3 articles (10/2019 - 01/2018)
2.	Chen, Qian: 2 articles (10/2019 - 01/2018)
3.	Gong, Zuo-Jiong: 2 articles (06/2018 - 01/2018)
4.	Jiao, Fang-Zhou: 2 articles (06/2018 - 01/2018)
5.	Zhang, Wen-Bin: 2 articles (06/2018 - 01/2018)
6.	Fang, Qin: 1 article (01/2020)
7.	Lu, Tingting: 1 article (01/2020)
8.	Ma, Dan: 1 article (01/2020)
9.	Wang, Jishi: 1 article (01/2020)
10.	Wang, Weili: 1 article (01/2020)

Related Diseases

1.	Acute Liver Failure (Fulminant Hepatic Failure) 01/01/2018 - "The purpose of this study was to investigate the protective mechanism of HDAC2 inhibitor CAY10683 on intestinal mucosal barrier in acute liver failure (ALF). " 10/01/2019 - "HDAC2 specific inhibitor CAY10683 was used to verify the protective effect on acute liver failure through reducing intestinal epithelial cell apoptosis by inhibiting mitochondrial apoptosis pathway. " 10/01/2019 - "HDAC2 inhibitor CAY10683 reduces intestinal epithelial cell apoptosis by inhibiting mitochondrial apoptosis pathway in acute liver failure." 01/01/2018 - "The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway."
2.	Neuroinflammatory Diseases 06/01/2018 - "The aim of present study was to investigate the effect of HDAC2 inhibitor CAY10683 on inflammatory responses and TLR4/NF-κB signaling pathways in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. " 06/01/2018 - "Moreover, CAY10683 increased the acetylation of histones H3 in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. " 06/01/2018 - "We found that CAY10683 could inhibit expression levels of inflammatory cytokine TNF-α and IL-1β in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. " 06/01/2018 - "Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-κB Signaling Pathway."
3.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/22/2013 - "Fractionation of the crude extract led to the isolation of a new cytotoxin, designated santacruzamate A (1), which has several structural features in common with suberoylanilide hydroxamic acid [(2), SAHA, trade name Vorinostat], a clinically approved histone deacetylase (HDAC) inhibitor used to treat refractory cutaneous T-cell lymphoma. "
4.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/02/2020 - "CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia."
5.	Pancreatic Neoplasms (Pancreatic Cancer) 11/25/2019 - "Furthermore, treatment of CAY10683, an HDAC2 inhibitor, and XAV939, a Wnt/β-catenin pathway inhibitor, attenuated the effects of ARHGAP4 silencing on pancreatic cancer cells. "

Related Drugs and Biologics

1.	Vorinostat
2.	Histone Deacetylase Inhibitors
3.	Histone Deacetylase 2
4.	Catenins
5.	Complex Mixtures
6.	Butyric Acid (Butanoic Acid)
7.	Cytokines
8.	Valproic Acid (Depakote)
9.	Lipopolysaccharides
10.	Hydroxamic Acids (Hydroxamic Acid)